Catalyst Wire Dossier Catalyst Wire Dossier

DE-109

DE-109 · Santen Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for DE-109, covering 2020-02-12 to 2020-02-12. Get the full timeline:

Most recent: Clinical Trial Update: A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program [Phase 3]

See pricing